| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.914 | 0.003 | 0.914 | Anticonvulsant | 0.689 0.005 DBMET03620 0.906 0.004 DBMET00444 0.733 0.005 DBMET00446 0.729 0.005 DBMET03615 0.335 0.032 DBMET03616 0.672 0.005 DBMET03617 0.364 0.027 DBMET03619 | ||
| 0.889 | 0.001 | 0.889 | Benzodiazepine agonist | 0.135 0.011 DBMET03620 0.568 0.002 DBMET00444 0.685 0.002 DBMET00446 0.435 0.003 DBMET03615 0.099 0.026 DBMET03616 0.115 0.018 DBMET03617 0.098 0.027 DBMET03618 0.106 0.022 DBMET03619 | ||
| 0.871 | 0.002 | 0.871 | GABA A receptor antagonist | 0.064 0.028 DBMET03620 0.76 0.002 DBMET00444 0.642 0.003 DBMET00446 0.469 0.003 DBMET03615 0.067 0.026 DBMET03616 0.059 0.031 DBMET03617 | ||
| 0.866 | 0.002 | 0.866 | GABA receptor antagonist | 0.071 0.025 DBMET03620 0.768 0.002 DBMET00444 0.631 0.003 DBMET00446 0.469 0.003 DBMET03615 0.077 0.023 DBMET03616 0.066 0.028 DBMET03617 | ||
| 0.819 | 0.002 | 0.819 | GABA receptor agonist | 0.169 0.027 DBMET03620 0.761 0.003 DBMET00444 0.679 0.003 DBMET00446 0.62 0.003 DBMET03615 0.174 0.025 DBMET03616 0.183 0.022 DBMET03617 0.138 0.043 DBMET03618 0.111 0.065 DBMET03619 | ||
| 0.654 | 0.004 | 0.654 | GABA C receptor rho-3 antagonist | 0.223 0.181 DBMET03620 0.511 0.023 DBMET00444 0.458 0.039 DBMET00446 0.265 0.142 DBMET03615 | ||
| 0.523 | 0.007 | 0.523 | Anesthetic general | 0.28 0.039 DBMET03620 0.423 0.014 DBMET00444 0.474 0.01 DBMET00446 0.34 0.025 DBMET03615 0.469 0.01 DBMET03616 0.228 0.06 DBMET03617 0.489 0.009 DBMET03618 0.202 0.073 DBMET03619 | ||
| 0.487 | 0.012 | 0.487 | Psychostimulant | 0.446 0.016 DBMET03620 0.413 0.02 DBMET00444 0.369 0.028 DBMET00446 0.285 0.047 DBMET03615 0.256 0.056 DBMET03616 0.433 0.018 DBMET03617 0.371 0.027 DBMET03618 0.31 0.04 DBMET03619 | ||
| 0.456 | 0.013 | 0.456 | Platelet aggregation inhibitor | 0.178 0.099 DBMET03620 0.223 0.066 DBMET00444 0.203 0.079 DBMET00446 0.142 0.139 DBMET03617 0.157 0.12 DBMET03618 | ||
| 0.418 | 0.005 | 0.418 | Platelet activating factor antagonist | 0.178 0.033 DBMET00444 0.193 0.028 DBMET00446 | ||
| 0.435 | 0.022 | 0.435 | HERG channel blocker | 0.164 0.115 DBMET00444 | ||
| 0.425 | 0.023 | 0.425 | Potassium channel (Voltage-sensitive) blocker | 0.157 0.131 DBMET00444 | ||
| 0.39 | 0.002 | 0.39 | Benzodiazepine antagonist | 0.058 0.015 DBMET03620 0.127 0.003 DBMET00444 0.126 0.003 DBMET00446 0.07 0.007 DBMET03615 0.046 0.035 DBMET03617 | ||
| 0.457 | 0.107 | 0.712 | Antiinflammatory | 0.478 0.097 DBMET03620 0.571 0.062 DBMET00444 0.315 0.202 DBMET03615 0.712 0.029 DBMET03616 0.569 0.062 DBMET03617 0.612 0.05 DBMET03618 0.289 0.226 DBMET03619 | DBMET03616 | |
| 0.401 | 0.084 | 0.401 | Analgesic | 0.351 0.108 DBMET00444 | ||
| 0.345 | 0.034 | 0.345 | Potassium channel blocker | |||
| 0.305 | 0.004 | 0.305 | GABA A receptor agonist | 0.262 0.005 DBMET00444 0.107 0.032 DBMET00446 0.097 0.04 DBMET03615 | ||
| 0.256 | 0.01 | 0.256 | GABA C receptor rho-2 antagonist | 0.185 0.038 DBMET00444 0.161 0.061 DBMET00446 | ||
| 0.308 | 0.078 | 0.507 | Immunomodulator | 0.44 0.034 DBMET03620 0.325 0.069 DBMET00444 0.487 0.025 DBMET03616 0.507 0.022 DBMET03617 0.365 0.055 DBMET03618 0.287 0.089 DBMET03619 | DBMET03617 | |
| 0.229 | 0.02 | 0.229 | Sodium channel (voltage-gated) blocker | 0.188 0.034 DBMET00444 0.11 0.097 DBMET00446 | ||
| 0.209 | 0.029 | 0.209 | Sodium channel blocker | 0.147 0.06 DBMET00444 | ||
| 0.174 | 0.013 | 0.174 | Potassium channel activator | 0.092 0.058 DBMET00444 0.121 0.032 DBMET00446 | ||
| 0.192 | 0.031 | 0.192 | MAP kinase kinase inhibitor | 0.118 0.076 DBMET00446 | ||
| 0.26 | 0.1 | 0.298 | Nootropic | 0.298 0.075 DBMET00444 | DBMET00444 | |
| 0.162 | 0.014 | 0.162 | Interleukin 2 antagonist | 0.113 0.057 DBMET00444 0.128 0.034 DBMET00446 0.105 0.076 DBMET03618 | ||
| 0.156 | 0.019 | 0.156 | p38 MAP kinase inhibitor | 0.092 0.035 DBMET00444 | ||
| 0.143 | 0.011 | 0.143 | Bromodomain-containing protein 2 inhibitor | 0.083 0.07 DBMET00444 0.09 0.056 DBMET00446 | ||
| 0.162 | 0.034 | 0.162 | Pregnane X receptor agonist | 0.138 0.079 DBMET00444 0.134 0.089 DBMET00446 | ||
| 0.145 | 0.019 | 0.145 | MAP kinase kinase 1 inhibitor | 0.09 0.071 DBMET00444 0.126 0.03 DBMET00446 | ||
| 0.134 | 0.017 | 0.134 | Glutamate (mGluR group I) antagonist | |||
| 0.218 | 0.104 | 0.218 | Cardiotonic | |||
| 0.159 | 0.047 | 0.159 | MAP kinase kinase 4 inhibitor | 0.131 0.112 DBMET03620 0.147 0.069 DBMET00444 0.153 0.055 DBMET00446 0.14 0.083 DBMET03615 | ||
| 0.134 | 0.027 | 0.152 | Alcohol dehydrogenase inhibitor | 0.089 0.065 DBMET03620 0.088 0.067 DBMET00444 0.138 0.025 DBMET00446 0.081 0.079 DBMET03615 0.089 0.065 DBMET03616 0.152 0.02 DBMET03618 | DBMET03618 | |
| 0.115 | 0.008 | 0.115 | Glutamate (mGluR5) antagonist | 0.046 0.033 DBMET00446 | ||
| 0.121 | 0.017 | 0.121 | Nav1.7 sodium channel blocker | 0.075 0.038 DBMET00444 | ||
| 0.165 | 0.065 | 0.165 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.123 | 0.025 | 0.123 | Glutamate (mGluR) antagonist | |||
| 0.305 | 0.206 | 0.305 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.1 | 0.004 | 0.1 | Benzodiazepine inverse agonist | 0.054 0.019 DBMET03620 0.086 0.005 DBMET00444 0.056 0.018 DBMET03616 0.054 0.02 DBMET03617 | ||
| 0.149 | 0.055 | 0.149 | Nav1.6 sodium channel blocker | 0.148 0.056 DBMET00446 0.124 0.09 DBMET03615 | ||
| 0.136 | 0.043 | 0.136 | MAP kinase 13 inhibitor | 0.095 0.089 DBMET00444 0.125 0.051 DBMET00446 0.099 0.083 DBMET03615 | ||
| 0.124 | 0.037 | 0.124 | GABA C receptor rho-1 antagonist | 0.091 0.076 DBMET00444 | ||
| 0.136 | 0.053 | 0.136 | MAP kinase 12 inhibitor | 0.103 0.094 DBMET00444 0.127 0.061 DBMET00446 0.107 0.088 DBMET03615 | ||
| 0.087 | 0.004 | 0.092 | Benzodiazepine receptor peripheral-type antagonist | 0.042 0.012 DBMET03620 0.064 0.005 DBMET00444 0.092 0.004 DBMET00446 0.076 0.004 DBMET03615 0.034 0.025 DBMET03616 0.039 0.015 DBMET03617 0.048 0.008 DBMET03618 0.05 0.007 DBMET03619 | DBMET00446 | |
| 0.128 | 0.045 | 0.128 | GABA C receptor antagonist | 0.096 0.084 DBMET00444 | ||
| 0.135 | 0.062 | 0.135 | Glutamate receptor antagonist | |||
| 0.098 | 0.026 | 0.098 | Transforming growth factor beta 3 antagonist | 0.085 0.048 DBMET00444 0.08 0.063 DBMET00446 | ||
| 0.123 | 0.051 | 0.123 | CDK3/cyclin E inhibitor | 0.115 0.063 DBMET00444 | ||
| 0.103 | 0.034 | 0.103 | MAP kinase 14 inhibitor | |||
| 0.085 | 0.016 | 0.085 | Phosphodiesterase 1C inhibitor | 0.06 0.048 DBMET00446 | ||
| 0.108 | 0.045 | 0.115 | Lanosterol 14 alpha demethylase inhibitor | 0.115 0.036 DBMET00444 0.092 0.069 DBMET00446 0.097 0.06 DBMET03615 | DBMET00444 | |
| 0.074 | 0.011 | 0.074 | Bromodomain-containing protein 3 inhibitor | 0.048 0.036 DBMET00444 0.06 0.021 DBMET00446 | ||
| 0.076 | 0.019 | 0.076 | Phosphodiesterase 1A inhibitor | |||
| 0.115 | 0.06 | 0.115 | 5 Hydroxytryptamine 3A agonist | |||
| 0.074 | 0.021 | 0.074 | Phosphodiesterase II inhibitor | 0.05 0.047 DBMET00444 | ||
| 0.174 | 0.125 | 0.174 | ErbB-1 antagonist | 0.164 0.145 DBMET00444 | ||
| 0.058 | 0.009 | 0.058 | 5 Hydroxytryptamine 2B agonist | |||
| 0.203 | 0.156 | 0.203 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.195 0.179 DBMET00444 | ||
| 0.074 | 0.027 | 0.074 | Phosphodiesterase 1B inhibitor | |||
| 0.066 | 0.02 | 0.066 | Phosphodiesterase 2A inhibitor | |||
| 0.06 | 0.02 | 0.06 | Farnesyltransferase inhibitor | 0.053 0.025 DBMET00444 | ||
| 0.099 | 0.059 | 0.099 | Pim-1 kinase inhibitor | 0.081 0.08 DBMET00446 | ||
| 0.054 | 0.016 | 0.054 | GABA B receptor antagonist | 0.048 0.022 DBMET00444 | ||
| 0.083 | 0.046 | 0.083 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.062 | 0.027 | 0.062 | Dihydroorotate dehydrogenase inhibitor | 0.049 0.039 DBMET00444 0.052 0.035 DBMET00446 | ||
| 0.069 | 0.039 | 0.069 | Aryl hydrocarbon receptor antagonist | |||
| 0.112 | 0.083 | 0.112 | Nav1.3 sodium channel blocker | |||
| 0.036 | 0.006 | 0.036 | Geranylgeranyltransferase I inhibitor | 0.031 0.008 DBMET00444 | ||
| 0.064 | 0.035 | 0.064 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.052 | 0.024 | 0.052 | Cholecystokinin antagonist | 0.035 0.032 DBMET00446 | ||
| 0.049 | 0.023 | 0.049 | Parathyroid hormone antagonist | 0.047 0.028 DBMET00444 0.043 0.037 DBMET00446 | ||
| 0.087 | 0.062 | 0.087 | Pim-3 kinase inhibitor | |||
| 0.071 | 0.047 | 0.071 | Transforming growth factor antagonist | |||
| 0.113 | 0.089 | 0.113 | Phosphodiesterase inhibitor | |||
| 0.063 | 0.039 | 0.063 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.05 | 0.032 | 0.05 | Purinergic P2X antagonist | |||
| 0.075 | 0.061 | 0.075 | Viral attachment inhibitor | |||
| 0.053 | 0.042 | 0.053 | Phosphodiesterase 4C inhibitor | |||
| 0.13 | 0.121 | 0.13 | LIM domain kinase 1 inhibitor | |||
| 0.036 | 0.027 | 0.036 | Cholecystokinin A antagonist | |||
| 0.052 | 0.043 | 0.052 | Bromodomain-containing protein 4 inhibitor | |||
| 0.075 | 0.066 | 0.075 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.091 | 0.083 | 0.091 | Hedgehog signaling inhibitor | |||
| 0.051 | 0.044 | 0.051 | Pim-2 kinase inhibitor | |||
| 0.047 | 0.041 | 0.047 | 5 Hydroxytryptamine 2 agonist | |||
| 0.081 | 0.075 | 0.081 | Phosphodiesterase I inhibitor | |||
| 0.107 | 0.103 | 0.107 | Cytokine production inhibitor | |||
| 0.097 | 0.094 | 0.097 | TRKA antagonist | |||
| 0.055 | 0.053 | 0.055 | Potassium channel (Ca-activated) blocker | |||
| 0.024 | 0.022 | 0.024 | Kynurenine 3 monooxygenase inhibitor | 0.024 0.021 DBMET00444 | ||
| 0.082 | 0.082 | 0.097 | DNA directed RNA polymerase inhibitor | 0.097 0.06 DBMET03620 0.091 0.067 DBMET03617 | DBMET03620 | |
| 0.035 | 0.048 | 0.042 | CF transmembrane conductance regulator antagonist | 0.042 0.021 DBMET00444 0.039 0.032 DBMET03615 | DBMET00444 | |
| 0.069 | 0.085 | 0.094 | Falcipain 2 inhibitor | 0.094 0.056 DBMET03616 | DBMET03616 | |
| 0.071 | 0.089 | 0.095 | Falcipain inhibitor | 0.095 0.058 DBMET03616 | DBMET03616 | |
| 0.057 | 0.084 | 0.067 | Protein kinase B beta inhibitor | 0.067 0.062 DBMET00446 | DBMET00446 | |
| 0.129 | 0.161 | 0.162 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.162 0.113 DBMET00446 0.148 0.13 DBMET03615 | DBMET00446 | |
| 0.124 | 0.157 | 0.215 | ATPase inhibitor | 0.174 0.065 DBMET03616 0.215 0.027 DBMET03618 | DBMET03618 | |
| 0.137 | 0.178 | 0.347 | Interleukin agonist | 0.307 0.045 DBMET03620 0.166 0.152 DBMET00444 0.347 0.03 DBMET03616 0.307 0.045 DBMET03617 0.24 0.086 DBMET03618 0.183 0.136 DBMET03619 | DBMET03616 | |
| 0.098 | 0.151 | 0.12 | Mannose-6-phosphate isomerase inhibitor | 0.12 0.1 DBMET03618 | DBMET03618 | |
| 0.071 | 0.133 | 0.095 | Glutamate release inhibitor | 0.095 0.051 DBMET03616 | DBMET03616 | |
| 0.063 | 0.139 | 0.107 | DNA intercalator | 0.107 0.067 DBMET03618 | DBMET03618 | |
| 0.081 | 0.159 | 0.112 | Interleukin 8 antagonist | 0.112 0.072 DBMET00446 | DBMET00446 | |
| 0.094 | 0.181 | 0.261 | NOS3 expression enhancer | 0.2 0.041 DBMET03620 0.261 0.024 DBMET03616 0.203 0.04 DBMET03617 0.214 0.036 DBMET03618 0.181 0.049 DBMET03619 | DBMET03616 | |
| 0.132 | 0.221 | 0.183 | MAP-kinase-activated kinase 5 inhibitor | 0.183 0.127 DBMET00446 0.162 0.161 DBMET03615 | DBMET00446 | |
| 0.105 | 0.201 | 0.219 | Non-steroidal antiinflammatory agent | 0.193 0.077 DBMET03616 0.219 0.058 DBMET03618 | DBMET03618 | |
| 0.061 | 0.158 | 0.084 | Protein kinase C zeta inhibitor | 0.084 0.078 DBMET03615 | DBMET03615 | |
| 0.159 | 0.262 | 0.269 | Toll-Like receptor 7 agonist | 0.269 0.131 DBMET00444 | DBMET00444 | |
| 0.09 | 0.193 | 0.199 | Insulin secretagoues | 0.141 0.084 DBMET03620 0.199 0.036 DBMET03616 0.13 0.097 DBMET03617 0.193 0.04 DBMET03618 | DBMET03616 | |
| 0.044 | 0.156 | 0.075 | Glycine receptor antagonist | 0.075 0.064 DBMET03616 | DBMET03616 | |
| 0.153 | 0.271 | 0.267 | Toll-Like receptor agonist | 0.267 0.134 DBMET00444 | DBMET00444 | |
| 0.059 | 0.179 | 0.197 | Beta glucuronidase inhibitor | 0.091 0.085 DBMET00446 0.142 0.029 DBMET03616 0.197 0.013 DBMET03618 0.092 0.084 DBMET03619 | DBMET03618 | |
| 0.054 | 0.201 | 0.115 | Cyclooxygenase 1 inhibitor | 0.115 0.085 DBMET00444 | DBMET00444 | |
| 0.103 | 0.266 | 0.216 | Cyclic AMP phosphodiesterase inhibitor | 0.216 0.083 DBMET03620 0.168 0.125 DBMET03617 | DBMET03620 | |
| 0.058 | 0.236 | 0.102 | Aldehyde dehydrogenase inhibitor | 0.102 0.094 DBMET03620 | DBMET03620 | |
| 0.056 | 0.237 | 0.118 | Protein kinase C nu inhibitor | 0.118 0.095 DBMET00446 | DBMET00446 | |
| 0.037 | 0.239 | 0.129 | Topoisomerase II inhibitor | 0.129 0.061 DBMET03616 0.118 0.068 DBMET03618 | DBMET03616 | |
| 0.112 | 0.316 | 0.237 | RNA-directed DNA polymerase inhibitor | 0.208 0.088 DBMET03620 0.237 0.058 DBMET03617 | DBMET03617 | |
| 0.106 | 0.312 | 0.319 | DNA synthesis inhibitor | 0.3 0.044 DBMET03620 0.185 0.145 DBMET03615 0.242 0.072 DBMET03616 0.319 0.038 DBMET03617 0.288 0.048 DBMET03618 0.309 0.041 DBMET03619 | DBMET03617 | |
| 0.117 | 0.325 | 0.276 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.276 0.083 DBMET00446 0.267 0.091 DBMET03615 | DBMET00446 | |
| 0.035 | 0.255 | 0.055 | Lipocortins synthesis agonist | 0.055 0.047 DBMET03616 0.055 0.05 DBMET03618 | DBMET03618 | |
| 0.005 | 0.243 | 0.033 | Sodium/glucose cotransporter 2 inhibitor | 0.033 0.011 DBMET03616 0.029 0.015 DBMET03617 0.026 0.018 DBMET03618 | DBMET03616 | |
| 0.007 | 0.257 | 0.031 | Sodium/glucose cotransporter inhibitor | 0.031 0.01 DBMET03616 0.028 0.014 DBMET03617 0.025 0.02 DBMET03618 | DBMET03616 | |
| 0.037 | 0.299 | 0.11 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.095 0.059 DBMET03620 0.11 0.046 DBMET03617 0.091 0.064 DBMET03619 | DBMET03617 | |
| 0.024 | 0.288 | 0.208 | Topoisomerase I inhibitor | 0.195 0.028 DBMET03620 0.143 0.044 DBMET03616 0.208 0.024 DBMET03617 0.137 0.046 DBMET03618 0.161 0.037 DBMET03619 | DBMET03617 | |
| 0.036 | 0.324 | 0.126 | Cytidine deaminase inhibitor | 0.126 0.095 DBMET03619 | DBMET03619 | |
| 0.051 | 0.373 | 0.132 | Hexokinase inhibitor | 0.126 0.109 DBMET03620 0.124 0.113 DBMET03617 0.132 0.102 DBMET03618 | DBMET03618 | |
| 0.039 | 0.396 | 0.108 | Cyclooxygenase 3 inhibitor | 0.108 0.092 DBMET03618 | DBMET03618 | |
| 0.032 | 0.393 | 0.112 | NADH dehydrogenase inhibitor | 0.09 0.057 DBMET03620 0.1 0.044 DBMET03616 0.112 0.033 DBMET03617 0.083 0.069 DBMET03619 | DBMET03617 | |
| 0.018 | 0.421 | 0.051 | Factor IXa inhibitor | 0.051 0.036 DBMET03618 | DBMET03618 | |
| 0.005 | 0.417 | 0.017 | S-adenosyl-L-homocysteine hydrolase inhibitor | 0.016 0.009 DBMET03620 0.017 0.008 DBMET03617 0.016 0.009 DBMET03619 | DBMET03617 | |
| 0.023 | 0.441 | 0.092 | Uric acid excretion stimulant | 0.092 0.062 DBMET03620 0.091 0.063 DBMET03617 0.085 0.074 DBMET03619 | DBMET03620 | |
| 0.015 | 0.437 | 0.064 | Heparanase inhibitor | 0.064 0.017 DBMET03616 0.058 0.026 DBMET03618 | DBMET03616 | |
| 0.08 | 0.506 | 0.234 | Caspase 3 stimulant | 0.195 0.177 DBMET03616 0.234 0.127 DBMET03618 | DBMET03618 | |
| 0.045 | 0.489 | 0.11 | DNA repair enzyme inhibitor | 0.11 0.097 DBMET03617 | DBMET03617 | |
| 0.025 | 0.484 | 0.163 | Anticoagulant | 0.163 0.07 DBMET03616 | DBMET03616 | |
| 0.036 | 0.5 | 0.265 | Tumour necrosis factor alpha release inhibitor | 0.265 0.068 DBMET03616 0.175 0.13 DBMET03618 | DBMET03616 | |
| 0.048 | 0.527 | 0.355 | Antithrombotic | 0.355 0.063 DBMET03616 0.316 0.079 DBMET03618 | DBMET03616 | |
| 0.017 | 0.513 | 0.104 | UDP-glucose 4-epimerase inhibitor | 0.104 0.056 DBMET03617 | DBMET03617 | |
| 0.017 | 0.537 | 0.11 | AMP-activated protein kinase stimulant | 0.091 0.085 DBMET03620 0.106 0.063 DBMET03616 0.11 0.059 DBMET03617 | DBMET03617 | |
| 0.075 | 0.613 | 0.127 | CC chemokine 6 receptor antagonist | 0.122 0.107 DBMET03616 0.127 0.081 DBMET03618 | DBMET03618 | |
| 0.026 | 0.575 | 0.157 | Hemostatic | 0.157 0.06 DBMET03616 0.149 0.069 DBMET03618 | DBMET03616 | |
| 0.019 | 0.571 | 0.127 | Cholinergic | 0.127 0.099 DBMET03618 | DBMET03618 | |
| 0.022 | 0.582 | 0.134 | Cell wall synthesis inhibitor | 0.134 0.082 DBMET03618 | DBMET03618 | |
| 0.02 | 0.586 | 0.061 | Adenine nucleotide translocase inhibitor | 0.06 0.029 DBMET03620 0.057 0.035 DBMET03616 0.061 0.026 DBMET03617 0.058 0.032 DBMET03619 | DBMET03617 | |
| 0.009 | 0.609 | 0.071 | Protein 50S ribosomal subunit inhibitor | 0.051 0.038 DBMET03620 0.07 0.024 DBMET03616 0.047 0.043 DBMET03617 0.071 0.023 DBMET03618 0.054 0.036 DBMET03619 | DBMET03618 | |
| 0.029 | 0.654 | 0.377 | Immunosuppressant | 0.263 0.138 DBMET03620 0.377 0.073 DBMET03616 0.279 0.129 DBMET03617 0.327 0.099 DBMET03618 0.248 0.149 DBMET03619 | DBMET03616 | |
| 0.009 | 0.636 | 0.027 | Toll-Like receptor 4 agonist | 0.027 0.017 DBMET03616 | DBMET03616 | |
| 0.019 | 0.646 | 0.129 | Interleukin 6 antagonist | 0.129 0.128 DBMET03618 | DBMET03618 | |
| 0.041 | 0.675 | 0.596 | Cyclophilin D inhibitor | 0.233 0.232 DBMET03620 0.596 0.028 DBMET03616 0.305 0.159 DBMET03617 0.401 0.09 DBMET03618 | DBMET03616 | |
| 0.003 | 0.643 | 0.036 | Adenosine A1 receptor agonist | 0.034 0.009 DBMET03620 0.036 0.009 DBMET03617 0.033 0.01 DBMET03619 | DBMET03617 | |
| 0.027 | 0.67 | 0.453 | Antibacterial | 0.217 0.21 DBMET03620 0.453 0.056 DBMET03616 0.222 0.205 DBMET03617 0.45 0.057 DBMET03618 0.229 0.197 DBMET03619 | DBMET03616 | |
| 0.017 | 0.667 | 0.215 | Vasodilator | 0.215 0.093 DBMET03616 0.165 0.136 DBMET03618 0.167 0.134 DBMET03619 | DBMET03616 | |
| 0.009 | 0.659 | 0.138 | Acetylcholinesterase inhibitor | 0.138 0.063 DBMET03618 | DBMET03618 | |
| 0.012 | 0.678 | 0.234 | Immunostimulant | 0.234 0.103 DBMET03616 0.191 0.126 DBMET03617 | DBMET03616 | |
| 0.019 | 0.687 | 0.143 | Toll-Like receptor 4 antagonist | 0.143 0.025 DBMET03616 0.098 0.073 DBMET03618 | DBMET03616 | |
| 0.004 | 0.686 | 0.015 | Adenosine A2b receptor agonist | 0.014 0.011 DBMET03620 0.015 0.01 DBMET03617 0.014 0.011 DBMET03619 | DBMET03617 | |
| 0.004 | 0.691 | 0.018 | Adenosine A3 receptor agonist | 0.018 0.011 DBMET03620 0.018 0.01 DBMET03617 0.018 0.011 DBMET03619 | DBMET03619 | |
| 0.013 | 0.72 | 0.221 | Nitric oxide antagonist | 0.221 0.06 DBMET03616 0.183 0.075 DBMET03618 | DBMET03616 | |
| 0.013 | 0.724 | 0.103 | Cell adhesion inhibitor | 0.103 0.084 DBMET03616 | DBMET03616 | |
| 0.054 | 0.785 | 0.418 | Interleukin 2 agonist | 0.418 0.023 DBMET03616 0.23 0.143 DBMET03617 0.305 0.07 DBMET03618 | DBMET03616 | |
| 0.024 | 0.767 | 0.373 | Hypoglycemic | 0.168 0.15 DBMET03620 0.373 0.033 DBMET03616 0.178 0.136 DBMET03617 0.337 0.041 DBMET03618 0.17 0.148 DBMET03619 | DBMET03616 | |
| 0.033 | 0.781 | 0.304 | Apoptosis antagonist | 0.304 0.083 DBMET03616 0.264 0.114 DBMET03618 0.195 0.186 DBMET03619 | DBMET03616 | |
| 0.009 | 0.788 | 0.192 | Thrombolytic | 0.192 0.056 DBMET03616 0.116 0.115 DBMET03618 | DBMET03616 | |
| 0.014 | 0.85 | 0.348 | Apoptosis agonist | 0.348 0.14 DBMET03616 0.271 0.194 DBMET03618 | DBMET03616 | |
| 0.018 | 0.87 | 0.268 | Hepatoprotectant | 0.151 0.109 DBMET03620 0.268 0.039 DBMET03616 0.164 0.095 DBMET03617 0.223 0.053 DBMET03618 | DBMET03616 | |
| 0.005 | 0.862 | 0.096 | Aminoacyl-tRNA synthetase inhibitor | 0.093 0.055 DBMET03620 0.096 0.05 DBMET03617 0.085 0.067 DBMET03619 | DBMET03617 | |
| 0.002 | 0.864 | 0.025 | Purinergic P2X agonist | 0.024 0.021 DBMET03620 0.025 0.021 DBMET03617 0.024 0.021 DBMET03619 | DBMET03617 | |
| 0.004 | 0.868 | 0.22 | Selectin antagonist | 0.22 0.009 DBMET03616 0.174 0.014 DBMET03618 | DBMET03616 | |
| 0.01 | 0.878 | 0.22 | Platelet adhesion inhibitor | 0.16 0.096 DBMET03620 0.203 0.07 DBMET03616 0.22 0.061 DBMET03617 0.148 0.108 DBMET03618 0.131 0.13 DBMET03619 | DBMET03617 | |
| 0.018 | 0.896 | 0.085 | Transcription factor NF kappa B stimulant | 0.082 0.066 DBMET03616 0.085 0.06 DBMET03618 | DBMET03618 | |
| 0.001 | 0.882 | 0.013 | Purinergic P2 agonist | 0.013 0.012 DBMET03617 | DBMET03617 | |
| 0.001 | 0.882 | 0.013 | Purinergic receptor agonist | 0.013 0.012 DBMET03617 | DBMET03617 | |
| 0.012 | 0.914 | 0.147 | DNA polymerase I inhibitor | 0.133 0.059 DBMET03620 0.147 0.051 DBMET03617 0.125 0.065 DBMET03619 | DBMET03617 | |
| 0.042 | 0.957 | 0.31 | Peptidyltransferase inhibitor | 0.291 0.028 DBMET03620 0.264 0.041 DBMET03616 0.282 0.032 DBMET03617 0.31 0.021 DBMET03618 0.284 0.031 DBMET03619 | DBMET03618 | |
| 0.005 | 0.929 | 0.241 | Free radical scavenger | 0.241 0.072 DBMET03616 0.212 0.088 DBMET03618 | DBMET03616 | |
| 0.003 | 0.966 | 0.05 | Antibiotic Aminoglycoside-like | 0.049 0.014 DBMET03616 0.05 0.013 DBMET03618 | DBMET03618 | |
| 0.005 | 0.971 | 0.388 | Angiogenesis stimulant | 0.174 0.108 DBMET03620 0.388 0.024 DBMET03616 0.207 0.091 DBMET03617 0.357 0.031 DBMET03618 0.156 0.119 DBMET03619 | DBMET03616 | |
| 0.004 | 0.974 | 0.277 | Antioxidant | 0.277 0.071 DBMET03616 0.273 0.073 DBMET03618 | DBMET03616 | |
| 0.002 | 0.977 | 0.031 | 1,3-Beta-glucan synthase inhibitor | 0.03 0.014 DBMET00446 0.031 0.013 DBMET03615 0.03 0.016 DBMET03619 | DBMET03615 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |